Drug Trial Radar · NCT02785185
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Aug 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jun 2016
Primary completion
Dec 2, 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
Conditions
- Psoriasis
Interventions
IDP-122 Vehicle LotionDrug
Vehicle
IDP-122 Vehicle CreamDrug
Vehicle
IDP-122 LotionDrug
Lotion
Ultravate CreamDrug
Cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 2Time frame: 2 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 05
Rogers, Arkansas
Valeant Site 10
Beverly Hills, California
Valeant Site 09
Carlsbad, California
Valeant Site 13
Los Angeles, California
Valeant Site 12
Santa Monica, California
Valeant Site 07
Coral Gables, Florida
Valeant Site 11
North Miami Beach, Florida
Valeant Site 03
Sanford, Florida
Valeant Site 08
Albany, Indiana
Valeant Site 04
Louisville, Kentucky
Valeant Site 06
Fridley, Minnesota
Valeant Site 02
High Point, North Carolina
Valeant Site 01
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.